Current and innovative approaches in the treatment of non-muscle invasive bladder cancer: the role of transurethral resection of bladder tumor and organoids
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
European Association of Urology. Guidelines. Non-invasive muscle bladder cancer. [cited 2019 Dec 15]. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/European Association of UrologyGuidelines. Non-invasive muscle bladder cancercited2019Dec 15Available athttps://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/Search in Google Scholar
European Commission. ECIS - European Cancer Information System. Incidence and mortality of bladder cancer in Europe. [cited 2018 Sep 15]. Available at: https://ecis.jrc.ec.europa.eu/explorer.php?$1-All$2-All$4-1,2$3-38$6-0,14$5-2008,2008$7-7,8$0-0$CEstByCountry$X0_8-3$CEstRelative$X1_8-3$X1_9-AE28European Commission. ECIS - European Cancer Information System. Incidence and mortality of bladder cancer in Europecited 2018 Sep 15Available athttps://ecis.jrc.ec.europa.eu/explorer.php?$1-All$2-All$4-1,2$3-38$6-0,14$5-2008,2008$7-7,8$0-0$CEstByCountry$X0_8-3$CEstRelative$X1_8-3$X1_9-AE28Search in Google Scholar
Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch 2015; 466: 589-94. doi: 10.1007/s00428-015-1739-2.CompératELarréSRoupretMNeuzilletYPignotGQuintensHet alClinicopathological characteristics of urothelial bladder cancer in patients less than 40 years oldVirchows Arch20154665899410.1007/s00428-015-1739-225697540Open DOISearch in Google Scholar
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-41. doi: 10.1016/j.eururo.2012.07.033BurgerMCattoJWDalbagniGGrossmanHBHerrHKarakiewiczPet alEpidemiology and risk factors of urothelial bladder cancerEur Urol2013632344110.1016/j.eururo.2012.07.03322877502Open DOISearch in Google Scholar
UICC International Union Against Cancer. Urinary bladder. In: Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. TNM classification of malignant tumours, 7th edition. Chichester: Wiley-Blackwell, 2009. p. 262-5.UICC International Union Against CancerUnion Against Cancer. Urinary bladderInSobinLHGospodarowiczMKWittekindCheditorsTNM classification of malignant tumours7th editionChichesterWiley-Blackwell2009p262510.1002/9780471420194.tnmc44.pub2Search in Google Scholar
Slora. Slovenia and cancer. Basic epidemiologic data on cancer. Urinary bladder (C67). [cited 2018 Mar 03]. Available at: http://www.slora.si/documents/11561/20219/bladder.pdf?version=1.2Slora. Slovenia and cancer. Basic epidemiologic data on cancer. Urinary bladder (C67)cited2018Mar 03Available athttp://www.slora.si/documents/11561/20219/bladder.pdf?version=1.2Search in Google Scholar
Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 2018; 173: 515-28.e17. doi: 10.1016/j.cell.2018.03.017LeeSHHuWMatulayJTSilvaMVOwczarekTBKimKet alTumor evolution and drug response in patient-derived organoid models of bladder cancerCell201817351528e1710.1016/j.cell.2018.03.017589094129625057Open DOISearch in Google Scholar
Wang S, Gao D, Chen Y. The potential of organoids in urological cancer research. Nat Rev Urol 2017; 14: 401-14. doi: 10.1038/nrurol.2017.65WangSGaoDChenYThe potential of organoids in urological cancer researchNat Rev Urol2017144011410.1038/nrurol.2017.65555805328534535Open DOISearch in Google Scholar
Zainfeld D, Daneshmand S. Transurethral resection of bladder tumors: improving quality through new techniques and technologies. Curr Urol Rep 2017; 18: 34. doi: 10.1007/s11934-017-0680-0ZainfeldDDaneshmandSTransurethral resection of bladder tumors: improving quality through new techniques and technologiesCurr Urol Rep2017183410.1007/s11934-017-0680-028283914Open DOISearch in Google Scholar
American Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline (2017). [2019 Dec 15]. Available at: https://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasiveAmerican Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline20172019 Dec 15Available athttps://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasiveSearch in Google Scholar
Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 2015; 9: E690-704. doi: 10.5489/cuaj.3320KassoufWTraboulsiSLKulkarniGSBreauRHZlottaAFaireyAet alCUA guidelines on the management of non-muscle invasive bladder cancerCan Urol Assoc J20159E69070410.5489/cuaj.3320466243326664503Open DOISearch in Google Scholar
Massarweh NN, Cosgriff N, Slakey DP. Electrosurgery: history, principles, and current and future uses. J Am Coll Surg 2006; 202: 520-30. doi: 10.1016/j. jamcollsurg.2005.11.017MassarwehNNCosgriffNSlakeyDPElectrosurgery: history, principles, and current and future usesJ Am Coll Surg20062025203010.1016/j.jamcollsurg.2005.11.01716500257Open DOISearch in Google Scholar
Osman Y, Harraz AM. A review comparing experience and results with bipolar versus monopolar resection for treatment of bladder tumors. Curr Urol Rep 2016; 17: 21. doi: 10.1007/s11934-016-0579-1OsmanYHarrazAMA review comparing experience and results with bipolar versus monopolar resection for treatment of bladder tumorsCurr Urol Rep2016172110.1007/s11934-016-0579-126874533Open DOISearch in Google Scholar
Mashni J, Godoy G, Haarer C, Dalbagni G, Reuter VE, Al-Ahmadie H, et al. Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. Int Urol Nephrol 2014; 46: 1699-705. doi: 10.1007/s11255-014-0719-9MashniJGodoyGHaarerCDalbagniGReuterVEAl-AhmadieHet alProspective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findingsInt Urol Nephrol201446169970510.1007/s11255-014-0719-9452477724792236Open DOISearch in Google Scholar
Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016; 69: 231-44. doi: 10.1016/j. eururo.2015.05.050SylvesterRJOosterlinckWHolmangSSydesMRBirtleAGudjonssonSet alSystematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?Eur Urol2016692314410.1016/j.eururo.2015.05.05026091833Open DOISearch in Google Scholar
Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intra-vesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008; 53: 709-19. doi: 10.1016/j.eururo.2008.01.015SylvesterRJOosterlinckWWitjesJAThe schedule and duration of intra-vesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trialsEur Urol2008537091910.1016/j.eururo.2008.01.015Open DOISearch in Google Scholar
Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 2016; 69: 1046-52. doi: 10.1016/j. eururo.2016.01.006ArendsTJNativOMaffezziniMde CobelliOCanepaGVerweijFet alResults of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancerEur Urol20166910465210.1016/j.eururo.2016.01.006Open DOISearch in Google Scholar
Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-56. doi: 10.1016/j.eururo.2009.04.038MalmstromPUSylvesterRJCrawfordDEFriedrichMKregeSRintalaEet alAn individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancerEur Urol2009562475610.1016/j.eururo.2009.04.038Open DOISearch in Google Scholar
van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44: 429-34. doi: 10.1016/s0302-2838(03)00357-9van der MeijdenAPSylvesterRJOosterlinckWHoeltlWBonoAVEORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III TrialEur Urol2003444293410.1016/s0302-2838(03)00357-9Open DOISearch in Google Scholar
Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3. doi: 10.1016/s0022-5347(17)58737-6MoralesAEidingerDBruceAWIntracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumorsJ Urol1976116180310.1016/s0022-5347(17)58737-6Open DOISearch in Google Scholar
Sylvester, RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70. doi: 10.1097/01.ju.0000034450.80198.1cSylvesterRJvan der MeijdenAPLammDLIntravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsJ Urol200216819647010.1097/01.ju.0000034450.80198.1c12394686Open DOISearch in Google Scholar
Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007; 52: 1398-406. doi: 10.1016/j. eururo.2007.04.062OjeaANogueiraJLSolsonaEFloresNGómezJMMolinaJRet alA multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin CEur Urol200752139840610.1016/j.eururo.2007.04.06217485161Open DOISearch in Google Scholar
Flsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol 2018; 15: 92-111. doi: 10.1038/nrurol.2017.179FlsensteinKMTheodorescuDPrecision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapyNat Rev Urol2018159211110.1038/nrurol.2017.17929133939Open DOISearch in Google Scholar
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-5. doi: 10.1038/nature07935SatoTVriesRGSnippertHJvan deWetering MBarkerNStangeDEet alSingle Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal nicheNature2009459262510.1038/nature0793519329995Open DOISearch in Google Scholar
Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180: 599-607. doi: 10.1016/j.ajpath.2011.10.036LiuXOryVChapmanSYuanHAlbaneseCKallakuryBet alROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cellsAm J Pathol201218059960710.1016/j.ajpath.2011.10.036334987622189618Open DOISearch in Google Scholar
Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest 2010; 120: 2619-26. doi: 10.1172/JCI42297ChapmanSLiuXMeyersCSchlegelRMcBrideAAHuman keratinocytes are efficiently immortalized by a Rho kinase inhibitorJ Clin Invest201012026192610.1172/JCI42297289860620516646Open DOISearch in Google Scholar
Santos CP, Lapi E, Martínez de Villarreal J, Alvaro-Espinosa L, Fernandez-Barral A, Barbáchano A, et al. Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity. Nat Commun 2019; 10: 4407. doi: 10.1038/s41467-019-12307-1.SantosCPLapiEMartínezde Villarreal JAlvaro-EspinosaLFernandez-BarralABarbáchanoAet alUrothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacityNat Commun201910440710.1038/s41467-019-12307-1676495931562298Open DOISearch in Google Scholar
Vasytin I, Zerihun L, Ivan C, Atala A. Bladder organoids and spheroids: potential tools for normal and diseased tissue modelling. Anticancer Res 2019; 39: 1105-18. doi: 10.21873/anticanres.13219VasytinIZerihunLIvanCAtalaABladder organoids and spheroids: potential tools for normal and diseased tissue modellingAnticancer Res20193911051810.21873/anticanres.1321930842139Open DOISearch in Google Scholar
Smith YC, Grande KK, Rasmussen SB, O’Brien AD. Novel three-dimensional organoid model for evaluation of the interaction of uropathogenic Escherichia coli with terminally differentiated human urothelial cells. Infect Immun 2006; 74: 750-7. doi: 10.1128/IAI.74.1.750-757.2006SmithYCGrandeKKRasmussenSBO’BrienADNovel three-dimensional organoid model for evaluation of the interaction of uropathogenic Escherichia coli with terminally differentiated human urothelial cellsInfect Immun200674750710.1128/IAI.74.1.750-757.2006134660416369034Open DOISearch in Google Scholar
Osborn SL, Thangappan R, Luria A, Lee JH, Nolta J, Kurzrock EA, et al. Induction of human embryonic and induced pluripotent stem cells into urothelium. Stem Cells Transl Med 2014; 3: 610-9. doi: 10.5966/sctm.2013-0131OsbornSLThangappanRLuriaALeeJHNoltaJKurzrockEAet alInduction of human embryonic and induced pluripotent stem cells into urotheliumStem Cells Transl Med20143610910.5966/sctm.2013-0131400648224657961Open DOISearch in Google Scholar
Kang M, Kim HH, Han YM. Generation of bladder urothelium from human pluripotent stem cells under chemically defined serum- and feeder-free system. Int J Mol Sci 2014; 15: 7139-57. doi: 10.3390/ijms15057139KangMKimHHHanYMGeneration of bladder urothelium from human pluripotent stem cells under chemically defined serum- and feeder-free systemInt J Mol Sci20141571395710.3390/ijms15057139405766424776760Open DOISearch in Google Scholar
Banerjee S, Southgate J. Bladder organoids a step towards personalised cancer therapy? Transl Androl Urol 2019; 8: S300-2. doi: 10.21037/tau.2019.06.10BanerjeeSSouthgateJBladder organoids a step towards personalised cancer therapy?Transl Androl Urol20198S300210.21037/tau.2019.06.10664295631392152Open DOISearch in Google Scholar
Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling of the tumor immune microenvironment. Cell 2018; 175: 1972-88. doi: 10.1016/j.cell.2018.11.021NealJTLiXZhuJGiangarraVGrzeskowiakCLJuJet alOrganoid modeling of the tumor immune microenvironmentCell201817519728810.1016/j.cell.2018.11.021665668730550791Open DOISearch in Google Scholar
Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: 134855. doi: 10.1200/JCO.2014.55.3487ScherHIHellerGMolinaAAttardGDanilaDCJiaXet alCirculating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerJ Clin Oncol20153313485510.1200/JCO.2014.55.3487439727925800753Open DOISearch in Google Scholar
Lozar T, Gersak K, Cemazar M, Grasic Kuhar C, Jesenko T. The biology and clinical potential of circulating tumor cells. Radiol Oncol 2019; 53: 131-47. doi: 10.2478/raon-2019-0024LozarTGersakKCemazarMGrasic KuharCJesenkoTThe biology and clinical potential of circulating tumor cellsRadiol Oncol2019531314710.2478/raon-2019-0024657249431104002Open DOISearch in Google Scholar
Shin K, Lee J, Guo N, Kim J, Lim A, Qu L, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 2011; 472: 110-4. doi: 10.1038/nature09851ShinKLeeJGuoNKimJLimAQuLet alHedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladderNature2011472110410.1038/nature09851367616921389986Open DOISearch in Google Scholar
Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S A 2019; 116: 4567-74. doi: 10.1073/pnas.1803595116.MullendersJde JonghEBrousaliARoosenMBlomJPABegthel, et alMouse and human urothelial cancer organoids: a tool for bladder cancer researchProc Natl Acad Sci U S A201911645677410.1073/pnas.1803595116641088330787188Open DOISearch in Google Scholar
